Tiziana Life Sciences LtdNASDAQ:TLSA
- LAST PRICE1.0200
- TODAY'S CHANGE (%)-0.0864 (-7.8091%)
- Bid / Lots1.0000/ 10
- Ask / Lots1.0500/ 425
- Open / Previous Close1.0800 / 1.1064
- Day Range
- 52 Week Range
- Volume253,772
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TLSA |
|---|---|---|
| 09:32 ET | 17779 | 1.0601 |
| 09:34 ET | 776 | 1.07 |
| 09:36 ET | 1812 | 1.0676 |
| 09:38 ET | 100 | 1.0812 |
| 09:43 ET | 14263 | 1.075 |
| 09:45 ET | 805 | 1.075 |
| 09:48 ET | 600 | 1.06 |
| 09:52 ET | 1801 | 1.0865 |
| 09:56 ET | 8304 | 1.0645 |
| 09:57 ET | 1400 | 1.0624 |
| 09:59 ET | 1000 | 1.075 |
| 10:01 ET | 339 | 1.07 |
| 10:03 ET | 100 | 1.07 |
| 10:06 ET | 100 | 1.06 |
| 10:08 ET | 1992 | 1.075 |
| 10:10 ET | 8604 | 1.05 |
| 10:15 ET | 1000 | 1.0481 |
| 10:17 ET | 700 | 1.03 |
| 10:19 ET | 3250 | 1.0222 |
| 10:21 ET | 120 | 1.0391 |
| 10:28 ET | 2999 | 1.02 |
| 10:30 ET | 12346 | 1.02 |
| 10:33 ET | 3300 | 1.035 |
| 10:37 ET | 2000 | 1.0354 |
| 10:44 ET | 2300 | 1.03 |
| 10:50 ET | 100 | 1.03 |
| 10:51 ET | 25065 | 1.02 |
| 10:53 ET | 32000 | 1.03 |
| 10:57 ET | 300 | 1.03 |
| 11:00 ET | 5000 | 1.04 |
| 11:02 ET | 3000 | 1.02 |
| 11:04 ET | 1074 | 1.0219 |
| 11:06 ET | 494 | 1.039 |
| 11:08 ET | 4000 | 1.0212 |
| 11:11 ET | 100 | 1.03 |
| 11:18 ET | 500 | 1.0264 |
| 11:20 ET | 3491 | 1.02 |
| 11:22 ET | 1400 | 1.0217 |
| 11:24 ET | 19636 | 1.04 |
| 11:27 ET | 200 | 1.035 |
| 11:31 ET | 200 | 1.05 |
| 11:36 ET | 1000 | 1.035 |
| 11:40 ET | 500 | 1.025 |
| 11:42 ET | 3222 | 1.0299 |
| 11:44 ET | 2982 | 1.0399 |
| 11:45 ET | 1000 | 1.0399 |
| 11:47 ET | 2100 | 1.035 |
| 11:49 ET | 128 | 1.04 |
| 11:51 ET | 200 | 1.04 |
| 11:56 ET | 1000 | 1.0481 |
| 12:02 ET | 200 | 1.0473 |
| 12:07 ET | 100 | 1.05 |
| 12:21 ET | 7000 | 1.03 |
| 12:25 ET | 2100 | 1.05 |
| 12:27 ET | 400 | 1.0365 |
| 12:39 ET | 800 | 1.035 |
| 12:43 ET | 900 | 1.035 |
| 12:48 ET | 100 | 1.04 |
| 12:50 ET | 400 | 1.04 |
| 01:06 ET | 100 | 1.03 |
| 01:14 ET | 600 | 1.035 |
| 01:17 ET | 500 | 1.035 |
| 01:21 ET | 800 | 1.03 |
| 01:28 ET | 200 | 1.03 |
| 01:30 ET | 3478 | 1.05 |
| 01:48 ET | 100 | 1.05 |
| 02:04 ET | 368 | 1.0374 |
| 02:08 ET | 100 | 1.05 |
| 02:11 ET | 188 | 1.0473 |
| 02:20 ET | 100 | 1.03 |
| 02:22 ET | 999 | 1.0371 |
| 02:26 ET | 100 | 1.05 |
| 02:31 ET | 400 | 1.04 |
| 02:44 ET | 100 | 1.05 |
| 02:56 ET | 100 | 1.04 |
| 02:58 ET | 552 | 1.0409 |
| 03:00 ET | 1500 | 1.0406 |
| 03:02 ET | 100 | 1.05 |
| 03:12 ET | 567 | 1.045 |
| 03:18 ET | 1352 | 1.05 |
| 03:23 ET | 200 | 1.045 |
| 03:27 ET | 200 | 1.045 |
| 03:32 ET | 100 | 1.05 |
| 03:41 ET | 100 | 1.05 |
| 03:43 ET | 710 | 1.04 |
| 03:45 ET | 2509 | 1.04 |
| 03:48 ET | 100 | 1.04 |
| 03:50 ET | 100 | 1.03 |
| 03:52 ET | 100 | 1.05 |
| 03:54 ET | 600 | 1.04 |
| 03:56 ET | 4900 | 1.03 |
| 03:57 ET | 2141 | 1.02 |
| 03:59 ET | 10984 | 1.02 |
Sep 19, 2024
Tiziana Life Sciences Announces $4 Million Grant Awarded by National Institutes of Health to Study Anti-CD3 in Alzheimer's Disease, from 7:00AM ET on Thursday Sep 19, 2024 by Dow Jones
7:00AM ET on Thursday Sep 19, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Tiziana Life Sciences Ltd | 114.1M | -5.9x | --- |
Verastem Inc | 113.9M | -0.9x | --- |
ALX Oncology Holdings Inc | 114.3M | -0.6x | --- |
Annovis Bio Inc | 112.8M | -1.9x | --- |
Regulus Therapeutics Inc | 111.9M | -1.4x | --- |
Fibrobiologics Inc | 111.1M | -3.5x | --- |
Company Information
Tiziana Life Sciences Ltd. is a United Kingdom-based clinical-stage biotechnology company. The Company develops transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Crohn's Disease and KRAS+ NSCLC. Its pipeline candidates include Foralumab (TZLS-401), Anti IL-6R mAb (TZLS-501) and Milciclib (TZLS-201). Foralumab (TZLS-401) is a fully human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn’s and neurodegenerative diseases. Its Anti IL-6R mAb (TZLS-501), a fully human mAb binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune disease and cancer, reducing circulating levels of the IL-6 cytokine. Milciclib is a potent, small molecule inhibitor of multiple cyclin-dependent kinases (CDKs), tropomycinreceptor kinases and Src family kinases controlling cell growth and malignant progression of cancer.
Contact Information
- Headquarters
- 3Rd Floor, 11-12 St. James's SquareLONDON, United Kingdom SW1Y 4LB
- Phone
- 207-495-2379
- Fax
- ---
Executives
- Executive Chairman of the Board
- Gabriele Cerrone
- Chief Executive Officer
- Ivor Elrifi
- Finance Director
- Keeren Shah
- Senior Director, CMC and Non - Clinical Development
- Jules Jacob
- Chief Development Officer
- William Clementi
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $114.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 103.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.44 |
EPS | $-0.17 |
Book Value | $0.05 |
P/E Ratio | -5.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
